Literature DB >> 3489800

Interleukin-2-induced chemotaxis of human T-lymphocytes.

R A Robbins, L Klassen, J Rasmussen, M E Clayton, W D Russ.   

Abstract

Interleukin-2 (IL-2), a growth factor for T-lymphocytes, has been postulated to cause the accumulation of T-lymphocytes at sites of inflammation by inducing proliferation of these cells. We hypothesized that IL-2 might also serve to attract T-lymphocytes to inflammatory sites. To test this hypothesis, human T-lymphocytes were purified from the peripheral blood of normal volunteers by rosetting with neuraminidase-treated sheep red blood cells and tested for chemotactic activity by using a blind-well chamber technique. Purified IL-2 caused a greater than 20-fold attraction of T-lymphocytes compared with medium alone (P less than 0.001). This attraction was shown to be chemotactic rather than chemokinetic by checkerboard analysis. The T-lymphocyte chemotaxis could be completely inhibited by adsorption of the IL-2 with an IL-2-dependent cell line, and could be neutralized by monoclonal anti-IL-2 antibody. Further specificity of IL-2-directed chemotaxis was demonstrated by using species-specific IL-2. Mouse IL-2 was ineffective at promoting human T-lymphocyte chemotaxis. These data suggest that IL-2 may be responsible for the localized accumulation of T-lymphocytes both by causing attraction of these cells and by modulating their proliferation.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3489800

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  3 in total

Review 1.  Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.

Authors:  Ruth Whittington; Diana Faulds
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

2.  Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.

Authors:  Keisuke Watanabe; Yanping Luo; Tong Da; Sonia Guedan; Marco Ruella; John Scholler; Brian Keith; Regina M Young; Boris Engels; Suvi Sorsa; Mikko Siurala; Riikka Havunen; Siri Tähtinen; Akseli Hemminki; Carl H June
Journal:  JCI Insight       Date:  2018-04-05

Review 3.  Win or loss? Combination therapy does improve the oncolytic virus therapy to pancreatic cancer.

Authors:  Wenhao Luo; Yawen Wang; Taiping Zhang
Journal:  Cancer Cell Int       Date:  2022-04-20       Impact factor: 6.429

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.